HISAMITSU PHARMACEUTICAL CO.,INC. Logo

HISAMITSU PHARMACEUTICAL CO.,INC.

A pharmaceutical firm specializing in external pain relief medications.

4530 | T

Overview

Corporate Details

ISIN(s):
JP3784600003
LEI:
Country:
Japan
Address:
鳥栖市田代大官町408番地

Description

Hisamitsu Pharmaceutical Co., Inc. is a pharmaceutical company that develops, manufactures, and markets a range of prescription and over-the-counter (OTC) products. The company specializes in external pain relief medications, utilizing advanced transdermal drug delivery system (TDDS) technology. Its core product portfolio includes topical analgesics and anti-inflammatory formulations, such as plasters, patches, and poultices. A key brand in its OTC segment is Salonpas, a globally recognized line of pain-relieving patches. The company serves both consumer healthcare and prescription markets worldwide, focusing on providing solutions for musculoskeletal pain and inflammation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-10-13 08:08
確認書
Japanese 9.5 KB
2022-10-13 08:07
四半期報告書-第121期第2四半期(令和4年6月1日-令和4年8月31日)
Japanese 247.2 KB
2022-07-08 07:55
四半期報告書-第121期第1四半期(令和4年3月1日-令和4年5月31日)
Japanese 183.4 KB
2022-05-27 07:32
確認書
Japanese 9.6 KB
2022-05-27 07:30
内部統制報告書-第120期(令和3年3月1日-令和4年2月28日)
Japanese 24.4 KB
2022-05-27 07:28
有価証券報告書-第120期(令和3年3月1日-令和4年2月28日)
Japanese 1.3 MB
2022-01-14 07:00
四半期報告書-第120期第3四半期(令和3年3月1日-令和3年11月30日)
Japanese 179.3 KB
2021-10-14 08:17
四半期報告書-第120期第2四半期(令和3年3月1日-令和3年8月31日)
Japanese 234.8 KB
2021-07-09 08:14
四半期報告書-第120期第1四半期(令和3年3月1日-令和3年5月31日)
Japanese 172.3 KB
2021-05-28 07:10
確認書
Japanese 9.6 KB
2021-05-28 07:06
内部統制報告書-第119期(令和2年3月1日-令和3年2月28日)
Japanese 24.4 KB
2021-05-28 07:02
有価証券報告書-第119期(令和2年3月1日-令和3年2月28日)
Japanese 1.2 MB
2021-01-14 03:26
四半期報告書-第119期第3四半期(令和2年9月1日-令和2年11月30日)
Japanese 177.8 KB
2020-10-09 02:34
四半期報告書-第119期第2四半期(令和2年6月1日-令和2年8月31日)
Japanese 231.2 KB
2020-07-10 04:00
四半期報告書-第119期第1四半期(令和2年3月1日-令和2年5月31日)
Japanese 171.3 KB

Automate Your Workflow. Get a real-time feed of all HISAMITSU PHARMACEUTICAL CO.,INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HISAMITSU PHARMACEUTICAL CO.,INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HISAMITSU PHARMACEUTICAL CO.,INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.